These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 23374588)

  • 1. Pharmacogenomics in Alzheimer's disease: a genome-wide association study of response to cholinesterase inhibitors.
    Martinelli-Boneschi F; Giacalone G; Magnani G; Biella G; Coppi E; Santangelo R; Brambilla P; Esposito F; Lupoli S; Clerici F; Benussi L; Ghidoni R; Galimberti D; Squitti R; Confaloni A; Bruno G; Pichler S; Mayhaus M; Riemenschneider M; Mariani C; Comi G; Scarpini E; Binetti G; Forloni G; Franceschi M; Albani D
    Neurobiol Aging; 2013 Jun; 34(6):1711.e7-13. PubMed ID: 23374588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of the choline acetyltransferase gene with responsiveness to acetylcholinesterase inhibitors in Alzheimer's disease.
    Yoon H; Myung W; Lim SW; Kang HS; Kim S; Won HH; Carroll BJ; Kim DK
    Pharmacopsychiatry; 2015 May; 48(3):111-7. PubMed ID: 25730470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A qualitative analysis of the mini mental state examination on Alzheimer's disease patients treated with cholinesterase inhibitors.
    Lucchi E; Minicuci N; Magnifico F; Mondini S; Calza A; Avanzi S; Villani D; Bellelli G; Trabucchi M
    Arch Gerontol Geriatr Suppl; 2004; (9):253-63. PubMed ID: 15207422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholinesterase inhibitors in Alzheimer's disease: efficacy in a non-selected population.
    Sinforiani E; Banchieri LM; Zucchella C; Bernasconi L; Nappi G
    Funct Neurol; 2003; 18(4):233-7. PubMed ID: 15055749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CHRNA7 Gene and Response to Cholinesterase Inhibitors in an Italian Cohort of Alzheimer's Disease Patients.
    Clarelli F; Mascia E; Santangelo R; Mazzeo S; Giacalone G; Galimberti D; Fusco F; Zuffi M; Fenoglio C; Franceschi M; Scarpini E; Forloni G; Magnani G; Comi G; Albani D; Martinelli Boneschi F
    J Alzheimers Dis; 2016 Apr; 52(4):1203-8. PubMed ID: 27104904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Follow-up study of susceptibility loci for Alzheimer's disease and onset age identified by genome-wide association.
    Bettens K; Brouwers N; Van Miegroet H; Gil A; Engelborghs S; De Deyn PP; Vandenberghe R; Van Broeckhoven C; Sleegers K
    J Alzheimers Dis; 2010; 19(4):1169-75. PubMed ID: 20308783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alteration of a clinically meaningful outcome in the natural history of Alzheimer's disease by cholinesterase inhibition.
    Lopez OL; Becker JT; Saxton J; Sweet RA; Klunk W; DeKosky ST
    J Am Geriatr Soc; 2005 Jan; 53(1):83-7. PubMed ID: 15667381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of apolipoprotein E and butyrylcholinesterase genotypes on cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer's disease.
    Patterson CE; Todd SA; Passmore AP
    Pharmacogenomics J; 2011 Dec; 11(6):444-50. PubMed ID: 20644562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toward an Alzheimer's disease diagnosis via high-resolution blood gene expression.
    Fehlbaum-Beurdeley P; Jarrige-Le Prado AC; Pallares D; Carrière J; Guihal C; Soucaille C; Rouet F; Drouin D; Sol O; Jordan H; Wu D; Lei L; Einstein R; Schweighoffer F; Bracco L
    Alzheimers Dement; 2010 Jan; 6(1):25-38. PubMed ID: 20129318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease.
    Karaman Y; Erdoğan F; Köseoğlu E; Turan T; Ersoy AO
    Dement Geriatr Cogn Disord; 2005; 19(1):51-6. PubMed ID: 15383747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease.
    Bartorelli L; Giraldi C; Saccardo M; Cammarata S; Bottini G; Fasanaro AM; Trequattrini A;
    Curr Med Res Opin; 2005 Nov; 21(11):1809-18. PubMed ID: 16307702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study.
    Mossello E; Tonon E; Caleri V; Tilli S; Cantini C; Cavallini MC; Bencini F; Mecacci R; Marini M; Bardelli F; Sarcone E; Razzi E; Biagini CA; Masotti G
    Arch Gerontol Geriatr Suppl; 2004; (9):297-307. PubMed ID: 15207427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apolipoprotein E epsilon4 allele differentiates the clinical response to donepezil in Alzheimer's disease.
    Bizzarro A; Marra C; Acciarri A; Valenza A; Tiziano FD; Brahe C; Masullo C
    Dement Geriatr Cogn Disord; 2005; 20(4):254-61. PubMed ID: 16103669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment pattern of Alzheimer's disease with cholinesterase inhibitors (TRAIN study)].
    Gil-Néciga E; Gobartt AL;
    Rev Neurol; 2008 Apr 16-30; 46(8):461-4. PubMed ID: 18428102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Replication study to confirm the role of CYP2D6 polymorphism rs1080985 on donepezil efficacy in Alzheimer's disease patients.
    Albani D; Martinelli Boneschi F; Biella G; Giacalone G; Lupoli S; Clerici F; Benussi L; Ghidoni R; Galimberti D; Squitti R; Mariani S; Confaloni A; Bruno G; Mariani C; Scarpini E; Binetti G; Magnani G; Franceschi M; Forloni G
    J Alzheimers Dis; 2012; 30(4):745-9. PubMed ID: 22465999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Responsiveness to cholinesterase inhibitors in Alzheimer's disease: a possible role for the 192 Q/R polymorphism of the PON-1 gene.
    Pola R; Flex A; Ciaburri M; Rovella E; Valiani A; Reali G; Silveri MC; Bernabei R
    Neurosci Lett; 2005 Jul; 382(3):338-41. PubMed ID: 15925115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of serum insulin-like growth factor-I levels to predict psychiatric non-response to donepezil in patients with Alzheimer's disease.
    Tei E; Yamamoto H; Watanabe T; Miyazaki A; Nakadate T; Kato N; Mimura M
    Growth Horm IGF Res; 2008 Feb; 18(1):47-54. PubMed ID: 17714966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypertension, white matter change and response to cholinesterase inhibitors in Alzheimer's disease.
    Connelly PJ; Prentice NP; Fowler KG
    Int J Geriatr Psychiatry; 2005 Jul; 20(7):623-8. PubMed ID: 16021654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period.
    López-Pousa S; Turon-Estrada A; Garre-Olmo J; Pericot-Nierga I; Lozano-Gallego M; Vilalta-Franch M; Hernández-Ferràndiz M; Morante-Muñoz V; Isern-Vila A; Gelada-Batlle E; Majó-Llopart J
    Dement Geriatr Cogn Disord; 2005; 19(4):189-95. PubMed ID: 15677866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic association of complement receptor 1 polymorphism rs3818361 in Alzheimer's disease.
    Antúnez C; Boada M; López-Arrieta J; Moreno-Rey C; Hernández I; Marín J; Gayán J; ; González-Pérez A; Real LM; Alegret M; Tárraga L; Ramírez-Lorca R; Ruiz A
    Alzheimers Dement; 2011 Jul; 7(4):e124-9. PubMed ID: 21784344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.